The Analyst Verdict: Editas Medicine In The Eyes Of 4 Experts
The Analyst Verdict: Editas Medicine In The Eyes Of 4 Experts
分析師的判決：4位專家眼中的Editas醫學
Across the recent three months, 4 analysts have shared their insights on Editas Medicine (NASDAQ:EDIT), expressing a variety of opinions spanning from bullish to bearish.
在最近三個月中，4位分析師分享了他們對Editas Medicine（納斯達克股票代碼：EDIT）的見解，表達了從看漲到看跌的各種觀點。
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
下表簡要介紹了他們最近的收視率，展示了過去30天中不斷變化的情緒，並將其與前幾個月進行了比較。
Analysts have set 12-month price targets for Editas Medicine, revealing an average target of $9.5, a high estimate of $15.00, and a low estimate of $7.00. Highlighting a 32.14% decrease, the current average has fallen from the previous average price target of $14.00.
分析師已經爲Editas Medicine設定了12個月的目標股價，顯示平均目標股價爲9.5美元，最高估計爲15.00美元，低估值爲7.00美元。當前的平均價格已從之前的平均目標股價14.00美元有所下降，這凸顯了32.14％的跌幅。
Investigating Analyst Ratings: An Elaborate Study
調查分析師評級：一項詳盡的研究
The standing of Editas Medicine...
通過對分析...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。